Distributor inventory
Dapagliflozin 10 mg + Glimepiride 2 mg + Metformin Hydrochloride 500 mg (Extended Release)
Type 2 diabetes mellitus: to improve blood sugar control in adults, as an adjunct to diet and exercise, when combination therapy is appropriate.
Dapagliflozin (SGLT2 inhibitor) lowers blood glucose by increasing urinary glucose excretion via the kidneys. Metformin (biguanide) reduces hepatic glucose production and improves insulin sensitivity. Glimepiride (sulfonylurea) increases insulin release from pancreatic beta cells.
Oral tablet (XR). Take exactly as prescribed, usually once daily with food (preferably with the evening meal) to reduce stomach upset and lower hypoglycaemia risk. Swallow whole; do not crush, break, or chew. Monitor blood glucose regularly.
Common side effects of GEMERDAPA XR 10/2/500 may include:
Risk of hypoglycaemia (higher with sulfonylurea), especially with missed meals/exercise/alcohol; monitor sugars. Metformin may rarely cause lactic acidosis—higher risk in kidney impairment, dehydration, severe infection, shock, liver disease, or heavy alcohol use; stop and seek care if rapid breathing, severe weakness, drowsiness occur. Dapagliflozin can cause genital infections, UTIs, volume depletion/low BP and may precipitate ketoacidosis (sometimes with near-normal sugars); seek urgent care for nausea/vomiting, abdominal pain, fast breathing. Kidney function should be assessed before and during treatment; not recommended in severe renal impairment. Temporarily withhold around major surgery or during acute illness/poor intake and before iodinated contrast procedures as advised by doctor.
